Kairos Pharma Ltd (AMEX: KAPA) kicked off on Tuesday, up 70.78% from the previous trading day, before settling in for the closing price of $0.69. Over the past 52 weeks, KAPA has traded in a range of $0.40-$4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -23.37% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 7.25%. With a float of $7.12 million, this company’s outstanding shares have now reached $15.83 million.
In an organization with 4 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kairos Pharma Ltd (KAPA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kairos Pharma Ltd is 57.73%, while institutional ownership is 9.36%. The most recent insider transaction that took place on Nov 25 ’24, was worth 318. In this transaction VP of Research and Development of this company bought 200 shares at a rate of $1.59, taking the stock ownership to the 133,057 shares. Before that another transaction happened on Nov 22 ’24, when Company’s Chief Financial Officer bought 2,500 for $1.50, making the entire transaction worth $3,750. This insider now owns 60,796 shares in total.
Kairos Pharma Ltd (KAPA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 7.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.45% during the next five years compared to -23.37% drop over the previous five years of trading.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Take a look at Kairos Pharma Ltd’s (KAPA) current performance indicators. Last quarter, stock had a quick ratio of 7.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.25, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Let’s dig in a bit further. During the last 5-days, its volume was 48.93 million. That was better than the volume of 3.35 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 54.76%.
During the past 100 days, Kairos Pharma Ltd’s (KAPA) raw stochastic average was set at 54.23%, which indicates a significant increase from 46.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1130 in the past 14 days, which was higher than the 0.1017 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6422, while its 200-day Moving Average is $1.1705. However, in the short run, Kairos Pharma Ltd’s stock first resistance to watch stands at $1.6533. Second resistance stands at $2.1367. The third major resistance level sits at $2.4533. If the price goes on to break the first support level at $0.8533, it is likely to go to the next support level at $0.5367. Assuming the price breaks the second support level, the third support level stands at $0.0533.
Kairos Pharma Ltd (AMEX: KAPA) Key Stats
The company with the Market Capitalisation of 19.71 million has total of 16,849K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -2,600 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -1,260 K.
